SIGNAL TRANSDUCT TAR 润色咨询

Signal Transduction and Targeted Therapy

出版年份:暂无数据 年文章数:500 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:暂无数据 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

投稿信息

投稿信息
审稿费用
暂无数据
版面费用
2880.0元/篇 (网友贡献,非官方数据)
中国人发表比例
2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
自引率
暂无数据
年文章数
500
期刊官网
点击查看 (点击次数:10855)
点击查看 (点击次数:6243次)
作者需知
点击查看 (点击次数:2268次)
期刊简介
稿件收录要求

Signal Transduction and Targeted Therapy (ISSN 2059-3635 (online), ISSN 2095-9907 (print), CN 51-1758/R) is a new open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It will include research on major human diseases, particularly on cancer. 

Signal Transduction and Targeted Therapy is a multidisciplinary journal, covering topics including but not limited to molecular biology, cell biology, pharmacology, medicinal chemistry, computational chemistry, systems biology, bioinformatics, and clinical medicine.

The editorial team of Signal Transduction and Targeted Therapy is composed of a highly respected editorial board of researchers from across the globe, led by the internationally renowned Professor Carlo M. Croce, together with Professor Kang Zhang and Professor Yu-Quan Wei.

This journal is now indexed in Pubmed Central (PMC) , Scopus, Directory of Open Access Journals (DOAJ) and BIOSIS.

Disclaimer

The editorial policies of this publication are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China.